Jan 16 (Reuters) - Rxi Pharmaceuticals Corp:
* RXI PHARMACEUTICALS ANNOUNCES BUSINESS STRATEGY TO FOCUS ON IMMUNO-ONCOLOGY PROGRAMS TO ACCELERATE GROWTH
* RXI PHARMACEUTICALS CORP - COMPANY TO “CAPITALIZE” ON PROPRIETARY SELF-DELIVERING RNAI PLATFORM (SD-RXRNA)
* RXI PHARMACEUTICALS CORP - 2018 BUSINESS STRATEGY INCLUDES DEVELOPING IMMUNO-ONCOLOGY TARGETS BEYOND CHECKPOINT INHIBITION, I.E. CELL DIFFERENTIATION
* RXI PHARMACEUTICALS- RELATING TO OPERATIONAL REVIEW, RXI INTENDS TO PARTNER/OUT-LICENSE BOTH ITS DERMATOLOGY AND OPHTHALMOLOGY FRANCHISES Source text for Eikon: Further company coverage:
 